255 related articles for article (PubMed ID: 36038960)
1. A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax
Kim HY; Cho JY; Yoon HJ; Choi YD; Ahn Y; Jeong MH; Cho JG; Kim KH
J Korean Med Sci; 2022 Aug; 37(34):e265. PubMed ID: 36038960
[TBL] [Abstract][Full Text] [Related]
2. Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase.
Macías Saint-Gerons D; Ibarz MT; Castro JL; Forés-Martos J; Tabarés-Seisdedos R
Drugs Real World Outcomes; 2023 Jun; 10(2):263-270. PubMed ID: 36788170
[TBL] [Abstract][Full Text] [Related]
3. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
Sharff KA; Dancoes DM; Longueil JL; Johnson ES; Lewis PF
Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):921-925. PubMed ID: 35404496
[TBL] [Abstract][Full Text] [Related]
4. Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
Smith K; Hegazy K; Cai MR; McKnight I; Rousculp MD; Alves K
Vaccine; 2023 Jun; 41(26):3930-3936. PubMed ID: 37211453
[TBL] [Abstract][Full Text] [Related]
5. Myopericarditis following COVID-19 vaccination in adolescent triplets.
Wong JW; Bock E; Kee WS; Anderson AJ; Kothari D; Tarca AJ
Cardiol Young; 2023 Nov; 33(11):2379-2383. PubMed ID: 37154289
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
[TBL] [Abstract][Full Text] [Related]
8. Myopericarditis following both BNT162b2 and NVX-CoV2373.
Ahmad S; Yuson C; Le A; Hissaria P
Allergy Asthma Clin Immunol; 2022 Dec; 18(1):109. PubMed ID: 36564782
[TBL] [Abstract][Full Text] [Related]
9. Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age.
Das BB; Kohli U; Ramachandran P; Nguyen HH; Greil G; Hussain T; Tandon A; Kane C; Avula S; Duru C; Hede S; Sharma K; Chowdhury D; Patel S; Mercer C; Chaudhuri NR; Patel B; Ang JY; Asmar B; Sanchez J; Khan D
J Pediatr; 2021 Nov; 238():26-32.e1. PubMed ID: 34339728
[TBL] [Abstract][Full Text] [Related]
10. Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents.
Schauer J; Buddhe S; Colyer J; Sagiv E; Law Y; Mallenahalli Chikkabyrappa S; Portman MA
J Pediatr; 2021 Nov; 238():317-320. PubMed ID: 34228985
[TBL] [Abstract][Full Text] [Related]
11. A paediatric case of myopericarditis post-COVID-19 mRNA vaccine.
Türe M; Akın A; Demir M; Akay C
Cardiol Young; 2022 Oct; 32(10):1688-1691. PubMed ID: 35082004
[TBL] [Abstract][Full Text] [Related]
12. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines.
Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ;
J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091
[TBL] [Abstract][Full Text] [Related]
13. A Case Report for Myopericarditis after BNT162b2 COVID-19 mRNA Vaccination in a Korean Young Male.
Kim D; Choi JH; Jang JY; So O; Cho E; Choi H; Hong KS; Park KT
J Korean Med Sci; 2021 Oct; 36(39):e277. PubMed ID: 34636504
[TBL] [Abstract][Full Text] [Related]
14. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
Kim S; Ko M; Heo Y; Lee YK; Kwon Y; Choi SK; Bahng E
Vaccine; 2023 Aug; 41(35):5066-5071. PubMed ID: 37422379
[TBL] [Abstract][Full Text] [Related]
15. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years - United States, July 2022.
Twentyman E; Wallace M; Roper LE; Anderson TC; Rubis AB; Fleming-Dutra KE; Hall E; Hsu J; Rosenblum HG; Godfrey M; Archer WR; Moulia DL; Daniel L; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(31):988-992. PubMed ID: 35925807
[TBL] [Abstract][Full Text] [Related]
16. Coronavirus disease 2019 vaccination-related pericarditis: a single tertiary-center experience.
Collini V; Imazio M; De Biasio M; Sinagra G
J Cardiovasc Med (Hagerstown); 2022 Dec; 23(12):779-783. PubMed ID: 36166325
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects.
Farahmand R; Trottier CA; Kannam JP; Ho KKL
Am J Cardiol; 2022 Feb; 164():123-130. PubMed ID: 34852929
[TBL] [Abstract][Full Text] [Related]
18. Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach.
Anastassopoulou C; Hatziantoniou S; Vlachopoulos C; Spanakis N; Tsioufis C; Tsakris A; Lazaros G
Int J Cardiol; 2022 Jul; 358():136-139. PubMed ID: 35436559
[TBL] [Abstract][Full Text] [Related]
19. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants.
Parums DV
Med Sci Monit; 2022 Mar; 28():e936523. PubMed ID: 35228506
[TBL] [Abstract][Full Text] [Related]
20. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
